i think the SP wont move in a big way till safety and efficacy results are known.If results are proven positive a takeover or at least investment by big pharma should be guaranteed
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress